TY - JOUR
T1 - Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics
T2 - Gastroenterology Enters the Metagenomics Era
AU - Preidis, Geoffrey A.
AU - Versalovic, James
N1 - Funding Information:
Funding This work was supported by National Institutes of Health (NIH) National Institute of Digestive and Kidney Disease (R01 DK065075 and P30 DK56338), NIH National Center for Complementary and Alternative Medicine (R01 AT004326 and R21 AT003482), and the US Department of Defense (HR0011-08-1-0009).
PY - 2009/5
Y1 - 2009/5
N2 - Studies of metagenomics and the human microbiome will tremendously expand our knowledge of the composition of microbial communities in the human body. As our understanding of microbial variation and corresponding genetic parameters is refined, this information can be applied to rational remodeling or "tailoring" of human-associated microbial communities and their associated functions. Physiologic features such as the development of innate and adaptive immunity, relative susceptibilities to infections, immune tolerance, bioavailability of nutrients, and intestinal barrier function may be modified by changing the composition and functions of the microbial communities. The specialty of gastroenterology will be affected profoundly by the ability to modify the gastrointestinal microbiota through the rational deployment of antibiotics, probiotics, and prebiotics. Antibiotics might be used to remove or suppress undesirable components of the human microbiome. Probiotics can introduce missing microbial components with known beneficial functions for the human host. Prebiotics can enhance the proliferation of beneficial microbes or probiotics, to maximize sustainable changes in the human microbiome. Combinations of these approaches might provide synergistic and effective therapies for specific disorders. The human microbiome could be manipulated by such "smart" strategies to prevent and treat acute gastroenteritis, antibiotic-associated diarrhea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and a variety of other disorders.
AB - Studies of metagenomics and the human microbiome will tremendously expand our knowledge of the composition of microbial communities in the human body. As our understanding of microbial variation and corresponding genetic parameters is refined, this information can be applied to rational remodeling or "tailoring" of human-associated microbial communities and their associated functions. Physiologic features such as the development of innate and adaptive immunity, relative susceptibilities to infections, immune tolerance, bioavailability of nutrients, and intestinal barrier function may be modified by changing the composition and functions of the microbial communities. The specialty of gastroenterology will be affected profoundly by the ability to modify the gastrointestinal microbiota through the rational deployment of antibiotics, probiotics, and prebiotics. Antibiotics might be used to remove or suppress undesirable components of the human microbiome. Probiotics can introduce missing microbial components with known beneficial functions for the human host. Prebiotics can enhance the proliferation of beneficial microbes or probiotics, to maximize sustainable changes in the human microbiome. Combinations of these approaches might provide synergistic and effective therapies for specific disorders. The human microbiome could be manipulated by such "smart" strategies to prevent and treat acute gastroenteritis, antibiotic-associated diarrhea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and a variety of other disorders.
UR - http://www.scopus.com/inward/record.url?scp=65449125343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65449125343&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2009.01.072
DO - 10.1053/j.gastro.2009.01.072
M3 - Article
C2 - 19462507
AN - SCOPUS:65449125343
SN - 0016-5085
VL - 136
SP - 2015
EP - 2031
JO - Gastroenterology
JF - Gastroenterology
IS - 6
ER -